Daily DPP-4 inhibitor

DRUG2 trials

Sponsors

Takeda, Haisco Pharmaceutical Group Co., Ltd.

Conditions

Type 2 Diabetes

Phase 2

A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients

CompletedNCT06703268

Haisco Pharmaceutical Group Co., Ltd.Type 2 Diabetes

Start: 2024-01-15End: 2024-11-20Updated: 2024-11-25

Phase 4

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

CompletedNCT03014479

TakedaType 2 Diabetes

Start: 2017-02-18End: 2017-10-21Updated: 2023-12-22

Related Papers

863-P: A Multicenter, Randomized, Open-Label, Controlled Study on Evaluating the Efficacy and Safety of Switching from Daily DPP-4 Inhibitors to Cofrogliptin in Patients with Type 2 Diabetes Mellitus in China

Diabetes2025-06-13

Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.

2019-06-187 citations